Junshi Biosciences

Shanghai Junshi Biosciences Co., Ltd. is an innovation-driven biopharmaceutical company dedicated to the discovery and development of innovative drugs. The company was founded by several returnees who graduated from prestigious American universities and have extensive experience in the transformation and industrialization of scientific and technological achievements. Relying on its capabilities in innovative drug discovery, biotechnology R&D, core platform technologies in protein engineering, and large-scale production technology across the entire industry chain, the company has developed a portfolio of drugs and taken a leading position in tumor immunotherapy, autoimmune disease treatment, and metabolic disease treatment. Junshi Biosciences has established several core technology platforms, including monoclonal antibody hybridoma, candidate antibody screening and evaluation, humanization (and de-immunogenicity), as well as the construction and screening system for high-expression mammalian cells for monoclonal antibody drugs. Its R&D pipeline includes 16 innovative drugs and 1 biosimilar, mainly covering major disease areas such as tumor immunotherapy, autoimmune diseases, cardiovascular diseases, and osteoporosis. Specific products include: PD-1 monoclonal antibody (JS001) for tumor immunotherapy, PCSK9 monoclonal antibody (JS002) for hypercholesterolemia treatment, and BLyS monoclonal antibody (UBP1213) for systemic lupus erythematosus treatment.